In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 2, 1999, Pages 115-125

  Wagner, Margaret M ^a   Paul, Donald C ^a   Shih, Chuan ^a   Jordan, Mary Ann ^b   Wilson, Leslie ^b   Williams, Daniel C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimitotic; Cell cycle; Cryptophycin; LY355703; Oncolytic

Indexed keywords

ANTINEOPLASTIC AGENT; CALCEIN; CRYPTOPHYCIN 52; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONOGENESIS; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; COLONY-FORMING UNITS ASSAY; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; HUMANS; LACTAMS; LACTONES; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; TUMOR CELLS, CULTURED;

EID: 0032903928     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050871     Document Type: Article

References (46)

1. Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E (1996) Characterization of the interaction of cryptophycin 1 with tubulin: binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res 56: 4398-4406
2. Barrow RA, Hemscheidt T, Liang J, Paik S, Moore RE, Tius MA (1995) Total synthesis of cryptophycins: revision to the structures of cryptophycins A and C. Am Chem Soc 117: 2479-2490
3. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910
4. Corbett T, Valeriote F, Simpson C, Moore R, Tius M, Barrow R, Hemscheidt T, Liang J, Paik S, Polin L, Pugh S, Kushner J, Harrison S, Shih C, Martinelli M (1997) Preclinical antitumor activity of cryptophycin-52/55 (C-52:C-55) against mouse tumors. Proc Am Assoc Cancer Res 38: 225 (abstract 1515)
5. Freshney RI (1987) Measurement of cytotoxicity and viability. In: Culture of animal cells: a manual of basic technique, 2nd edn. Wiley-Liss, New York Chichester Brisbane Toronto Singapore. pp 246-248
6. Golakoti T, Ogino J, Heltzel CE, Husebo TL, Jensen CM, Larsen LK, Patterson GML, Moore RE, Mooberry SL, Corbett TH, Valeriote FA (1995) Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. Strains GSV 224. J Am Chem Soc 117(49): 12030-12049
7. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361
8. Hamel E (1996) Antimitotic natural products and their interactions with tubulin. Med Res Rev 16: 207-231
9. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, Watts P, Speicher L, Tew K, Comis R (1992) Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761
10. Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R (1995) Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol 22(3) [Suppl 6]: 6-11
11. Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C (1995) Paclitaxel plus estramustine in metastatic hormone refractory prostate cancer. Semin Oncol 22(5) [Suppl 12]: 41-45
12. Jacobs AD, Gale RP (1984) Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. N Engl J Med 311: 1219-1231
13. Johnson IS, Wright HF, Svoboda GH, Vlantis J (1960) Antitumor principles derived from vinca rosea Linn: I. Vinca leucoblastine and leurosine. Cancer Res 20: 1016-1022
14. Johnson SA, Harper P, Hortobagyi GN, Pouillart P (1996) Vinorelbine: an overview. Cancer Treat Rev 22: 127-144
15. Jordan MA, Wilson L (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130
16. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556
17. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816-825
18. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI, Himes RH (1995) Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett 377: 59-61
19. Marsh W, Center MS (1987) Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells. Cancer Res 47: 5080-8086
20. McGrath T, Center MS (1987) Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 145: 1171-1176
21. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS (1989) Mechanisms of multidrug resistance in HL60 cells: analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem Pharmacol 38(20): 3611-3619
22. McKenna SL, Padua RA (1997) Multidrug resistance in leukemia. Br J Haematol 96: 659-674
23. Mooberry SL, Taoka CR, Busquets L (1996) Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site. Cancer Lett 107: 53-57
24. Nooter K, Stoter G (1996) Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768-780
25. Panda D, Williams DC, Wagner MM, Paul DC, Habeck LL, Mendelsohn LG, Shih C, Moore RE, Wilson L (1997) Inhibition of microtubule polymerization and dynamics by two novel cryptophycins, cryptophycins 52 and 55. Proc Am Assoc Cancer Res 38: 225 (abstract 1517)
26. Panda D, Miller HP, Islam K, Wilson L (1997) Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci U S A 94: 10560-10564
27. Panda D, Himes RH, Moore RS, Wilson L, Jordan MA (1997) Mechanism of action of the unusually potent microtubule inhibitor, cryptophycin 1. Biochemistry 36: 12948-12953
28. Panda D, DeLuca K, Williams D, Jordan MA, Wilson L (1998) Antiproliferative mechanism of action of cryptophycin 52: kinetic stabilization of microtubule dynamics by high affinity binding to microtubule ends. Proc Natl Acad Sci USA 95: 9313-9318
29. Paul S, Breuninger LM, Kruh GD (1996) ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Biochemistry 35(44): 14003-14011
30. Polin L, Valeriote F, Moore R, Tius M, Barrow R, Hemscheidt T, Liang J, Paik S, White K, Harrison S, Shih C, Martinelli M, Corbett T (1997) Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against human tumors in SCID mice. Proc Am Assoc Cancer Res 38: 225 (abstract 1514)
31. IVa-tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56: 2584-2589
32. Roepe PD, Wei L, Hoffman MM, Friederike F (1996) Altered drug translocation mediated by the MDR protein: direct, indirect, or both? J Bioenerg Biomembr 28: 541-555
33. Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-374
34. Schibler MJ, Cabral F (1986) Taxol-dependent mutants of chinese hamster ovary cells with alterations in α- and β-tubulin. J Cell Biol 102: 1522-1531
35. Schultz RM, Shih C, Harrison S, Martinelli MJ, Toth JE, Andis SL (1997) In vitro antiproliferative activity of the epoxide cryptophycin analogue, LY355703. Proc Am Assoc Cancer Res 38: 225 (abstract 1518)
36. Schwartz RE, Hirsch CF, Sesubm DF, Flor JE, Chartrain M, Fromtling RE, Harris GH, Salvatore MJ, Liwaxh JM, Yudin K (1990) Pharmaceuticals from cultured algae. J Indian Microbiol 5: 113-124
37. Slapak CA, Mizunuma N, Kufe DW (1994) Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 84: 3113-3121
38. Smith CD, Zhang X (1996) Mechanism of action of cryptophycin. Interaction with the vinca alkaloid domain of tubulin. J Biol Chem 271: 6192-6198
39. Smith CD, Zhang X, Mooberry SL, Patterson GML, Moore RE (1994) Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54: 3779-3784
40. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, Mendelsohn LG (1997) Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39: 521-531
41. Trimurtulu G, Ohtani I, Patterson GML, Moore RE, Corbett TH, Valeriote FA, Demchik L (1994) Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. strain GSV. J Am Chem Soc 116: 4729-4737
42. Williams DC, Paul DC, Wagner MM, Slapak CA (1997) Daunorubicin, paclitaxel Bodipy® FL, rhodamine 123 and the fluorescent lysosomal probes LysoSensor™ yellow/blue and acridine orange accumulate in a common vesicular compartment in multidrug resistant U-A10 myeloid leukemia cells. Proc Am Assoc Cancer Res 38: 386 (abstract 2589)
43. Williams DC, Wagner MM, Law KL, Shepard RL, Paul DC, Starling JJ, Dantzig AH, Moore RE, Shih C (1997) In vitro pharmacology of cryptophycin 52 (LY355703) and cryptophycin 55 (LY355702) in human tumor cell lines. Proc Am Assoc Cancer Res 38: 226 (abstract 1519)
44. Williams DC, Wagner MM, Paul DC, Jordan MA, Wilson L, Shih C (1998) The mechanism of action of cryptophycin 52 (LY355703): cellular effects on human colon carcinoma cell lines HT-29 and Caco-2 (in press)
45. Worzalla JF, Cao J, Ehlhardt WJ, Harrison SD, Law KL, Martinelli MJ, Self TD, Starling JJ, Shih C, Theobald KS, Toth JE, Zimmermann JL, Corbett TH (1997) LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts. Proc Am Assoc Cancer Res 38: 225 (abstract 1516)
46. Zaman GJR, Flens MJ, vanLeusden MR, deHaas M, Mulder H, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-882